Lrrk2 and Lewy body disease

Owen A. Ross, Mathias Toft, Andrew J. Whittle, Joseph L. Johnson, Spiridon Papapetropoulos, Deborah C. Mash, Irene Litvan, Mark F. Gordon, Zbigniew K. Wszolek, Matthew J. Farrer, Dennis W. Dickson

Research output: Contribution to journalArticlepeer-review

206 Scopus citations

Abstract

Objective: The Lrrk2 kinase domain G2019S substitution is the most common genetic basis of familial and sporadic parkinsonism. Patients harboring the G2019S substitution usually present with clinical Parkinson's disease. Methods: Herein, we report that the most common neuropathology of G2019S-associated Parkinson's disease is Lewy body disease. Results: Lrrk2 G2019S was observed in approximately 2% (n = 8) of our Parkinson's disease/Lewy body disease cases (n = 405). The mutation was also found in one control subject and one Alzheimer's disease patient, reflecting reduced penetrance. Interpretation: Therapeutic strategies targeted at modulating Lrrk2 kinase activity may be important to treat patients with genetically defined familial or typical sporadic Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)388-393
Number of pages6
JournalAnnals of Neurology
Volume59
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint Dive into the research topics of 'Lrrk2 and Lewy body disease'. Together they form a unique fingerprint.

Cite this